Article Text

Download PDFPDF
194 Natalizumab treatment for MS: UK and global results from TOP
  1. Richard Nicholas1,
  2. Timothy Harrower2,
  3. Xiaoyu Jiang3,
  4. Stephanie Licata3,
  5. Jean Vonsy4
  1. 1Imperial College Healthcare NHS Trust, London
  2. 2Royal Devon and Exeter NHS Trust, Exeter
  3. 3Biogen, Cambridge, MA, USA
  4. 4Biogen, Maidenhead


Introduction The TYSABRI Observational Program (TOP) is the largest real-world study in natalizumab-treated relapsing-remitting MS patients. Country-specific data, alongside global data, can provide information on natalizumab’s effectiveness in local practice.

Methods Annualised relapse rate (ARR) and cumulative probability of 24-week confirmed disability worsening (CDW; Expanded Disability Status Scale [EDSS] score increase from baseline of ≥1.5 from 0.0, ≥1.0 from 1.0–5.5, or ≥0.5 from ≥6.0) and improvement (CDI; decrease ≥1.0 from baseline EDSS score ≥2.0) over 6 years were analysed in TOP UK (n=134) and global (N=6149) cohorts using data from July 2007 to November 2017.

Results ARR decreased in UK patients from 2.21 in the year before initiation to 0.21 on natalizumab, paralleling the global decrease from 1.99 to 0.21. At 6 years, probabilities of CDW and CDI were, respectively, 27.8% and 34.4% in UK patients and 24.2% and 32.0% globally.

Conclusions Consistent with global TOP results, natalizumab ARRs and disability worsening rates remained low and disability improvement rates exceeded 30% at 6 years in the UK cohort. These results support natalizumab’s long-term effectiveness in real-world settings.

Support: Biogen. Disclosures will be included on the poster.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.